Silo Pharma, Inc. / Fundamentals

    Income statement

    Net revenue
    €62.19K
    Cost of goods sold
    €5.04K
    Gross profit
    €57.16K
    SG&A expenses
    €1.23M
    R&D expenses
    €2.51M
    EBITDA
    -€4.36M
    D&A
    €7.47K
    EBIT
    -€4.46M
    Interest expenses
    -€2.03K
    EBT
    -€4.22M
    Tax expenses
    €0.00
    Net income
    -€4.22M

    Cash flow statement

    Net deferred tax
    €0.00
    Non-cash items
    -€2.13M
    Changes in working capital
    €472.49K
    Operating cash flow
    -€4.48M
    Capex
    €2.59
    Other investing cash flow
    €1.09M
    Net investing cash flow
    €1.02M
    Total cash dividends paid
    €0.00
    Issuance of common stock
    €3.31M
    Debt repayment
    €0.00
    Other financing cash flow
    €1.50M
    Net financing cash flow
    €3.31M
    Foreign exchange effects
    €0.00
    Net change in cash
    -€148.91K
    Cash at end of period
    €3.74M
    Free cash flow
    -€4.48M

    Balance sheet

    Cash and cash equivalents
    €3.74M
    Cash and short-term investments
    €5.40M
    Total receivables
    €0.00
    Inventory
    €0.00
    Other current assets
    €97.53K
    Total current assets
    €5.50M
    Property, plant & equipment
    €0.00
    Goodwill
    €0.00
    Intangible assets
    €192.57K
    Long-term investments
    €0.00
    Other non-current assets
    -€5.45M
    Total non-current assets
    -€5.26M
    Total assets
    €5.74M
    Accounts payable
    €843.44K
    Short-term debt
    €0.00
    Other current liabilities
    €0.00
    Total current liabilities
    €905.63K
    Long-term debt
    €0.00
    Deferred tax liabilities
    €0.00
    Other non-current liabilities
    €0.00
    Total non-current liabilities
    €591.33K
    Total liabilities
    €1.50M
    Common stock
    €746.14
    Retained earnings
    -€15.10M
    Other equity
    €8.25K
    Total equity
    €4.24M
    Total liabilities and shareholders' equity
    €5.74M

    Company information

    Market capitalization
    €3.94M
    Employees
    3
    Enterprise Value
    €1.12M

    Company ratios

    Gross margin
    91.9% Much worse than peer group: 137,802,520,687,132,380.0%
    EBITDA margin
    -7,015.7% Much worse than peer group: 5,101,858,965,149,129,000.0%
    EBIT margin
    -7,165.0% Much worse than peer group: 5,475,139,268,353,223,000.0%
    EBT margin
    -6,789.2% Much worse than peer group: 5,673,538,150,803,845,000.0%
    Net margin
    -6,789.2% Much worse than peer group: 2,133,946,780,268,117,600.0%
    ROE
    -99.6% Much better than peer group: -136.8%
    ROA
    -73.6% Much better than peer group: -230.9%
    Asset turnover
    1.1% Much worse than peer group: 559.2%
    FCF margin
    -7,197.4% Much worse than peer group: 3,257,161,346,136,870,800.0%
    FCF yield
    -113.6%
    Efficiency ratio
    7,115.7%
    Net sales per employee
    €20.73K
    Net income per employee
    -€1.41M

    Notifications